BioCorRx’s Subsidiary, BioCorRx Pharmaceuticals, to Exhibit at ASAM 50th Annual Conference in Orlando, Florida
28 mars 2019 08h00 HE
|
BioCorRx Inc
ANAHEIM, CA, March 28, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company), a developer and provider of advanced solutions in the treatment of substance abuse...
BioCorRx Promotes Dr. Balbir S. Brar to Senior VP of Drug Development; Extends Service Agreement
27 mars 2019 07h37 HE
|
BioCorRx Inc
ANAHEIM, CA, March 27, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTC: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of substance abuse...
BioCorRx Announces Formation of Scientific Advisory Board
19 févr. 2019 10h26 HE
|
BioCorRx Inc
ANAHEIM, CA, Feb. 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...
BioCorRx Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market
23 janv. 2019 08h00 HE
|
BioCorRx Inc
ANAHEIM, CA, Jan. 23, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX; BICXD) (the “Company”), a developer and provider of advanced solutions in the treatment of substance...
BioCorRx Awarded NIDA Grant of Approximately $5.7 Million for BICX102, a Sustained Release Naltrexone Implant for the Treatment of Opioid Use Disorder
22 janv. 2019 07h30 HE
|
BioCorRx Inc
ANAHEIM, CA, Jan. 22, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...
BioCorRx Provides Business Update for the Third Quarter of 2018
14 nov. 2018 08h00 HE
|
BioCorRx, Inc.
ANAHEIM, CA, Nov. 14, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – BioCorRx, Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...
BioCorRx Strengthens Intellectual Property Portfolio with Acquisition of Several Patent/Patent Pending Families
19 oct. 2018 07h30 HE
|
BioCorRx Inc
Issued patents, in addition to other intellectual property (IP) rights, cover hydrophobic drug-delivery material for BICX101 Divisional patent applications filed to strengthen BioCorRx’s ...
BioCorRx, Inc. Announces Preliminary Agreement with VDM Biochemicals to Develop and Commercialize Patented Opioid Antagonist VDM-001
09 oct. 2018 08h00 HE
|
BioCorRx Inc
ANAHEIM, CA, Oct. 09, 2018 (GLOBE NEWSWIRE) -- VDM-001 represents potential alternative to naloxone for overdose reversal; Potential to reduce cravings from substance use disorder via...
BioCorRx to Exhibit at the International Association of Chiefs of Police 2018 Annual Conference in Orlando, Florida
05 oct. 2018 07h30 HE
|
BioCorRx Inc
ANAHEIM, CA, Oct. 05, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid...
BioCorRx Provides BICX102 Grant Update
02 oct. 2018 07h51 HE
|
BioCorRx Inc
ANAHEIM, CA, Oct. 02, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...